These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 32189591)
1. Anti-VEGF Treatment in Corneal Diseases. Giannaccare G; Pellegrini M; Bovone C; Spena R; Senni C; Scorcia V; Busin M Curr Drug Targets; 2020; 21(12):1159-1180. PubMed ID: 32189591 [TBL] [Abstract][Full Text] [Related]
2. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316 [TBL] [Abstract][Full Text] [Related]
3. [The effectiveness and safety evaluation of anti-VEGF drugs on the treatment of corneal neovascularization]. Wu X; Yang F Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):730-3. PubMed ID: 26693766 [TBL] [Abstract][Full Text] [Related]
4. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712 [TBL] [Abstract][Full Text] [Related]
5. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Hosseini H; Nejabat M Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753 [TBL] [Abstract][Full Text] [Related]
7. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Al-Debasi T; Al-Bekairy A; Al-Katheri A; Al Harbi S; Mansour M Saudi J Ophthalmol; 2017; 31(2):99-105. PubMed ID: 28559722 [TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572 [TBL] [Abstract][Full Text] [Related]
9. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model. Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219 [TBL] [Abstract][Full Text] [Related]
10. The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization. Eski MT; Teberik K; Oltulu P; Ankaralı H; Kaya M; Alpay M Hum Exp Toxicol; 2022; 41():9603271221084674. PubMed ID: 35465742 [TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits. Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293 [TBL] [Abstract][Full Text] [Related]
12. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Stevenson W; Cheng SF; Dastjerdi MH; Ferrari G; Dana R Ocul Surf; 2012 Apr; 10(2):67-83. PubMed ID: 22482468 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization. Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Han YS; Lee JE; Jung JW; Lee JS Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of a novel PIGF-1 derived peptide, ZY-1, on corneal neovascularization in vitro and in vivo. Lu Y; Zheng Y; Ai J; Xu X Discov Med; 2016 May; 21(117):349-61. PubMed ID: 27355331 [TBL] [Abstract][Full Text] [Related]
17. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P; Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975 [TBL] [Abstract][Full Text] [Related]
18. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Tolentino M Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144 [TBL] [Abstract][Full Text] [Related]